Press Releases

 
Press Releases
  Date Title and Summary View
Apr 9, 2013
Fremont, CA — April 9, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today that Chris Krueger has been appointed as the company's Chief Business Officer. In this position, Mr. Krueger will be responsible for the company's business devel...
Oct 11, 2011
FREMONT, Calif. and TOKYO, Oct. 10, 2011 /PRNewswire/ — Zosano Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) announced today that they have entered into a long–term strategic collaboration for the development, commercialization and supply of a weekly transdermal patch formulation of Teribone™ (teriparatide acet...
Jan 20, 2010
Fremont, Calif. January 20, 2010 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Dr. Peter Daddona, the company’s chief scientific officer, will present at the 14th Annual Drug Delivery Partnerships Meeting in Orlando, Florida ...
Nov 9, 2009
Fremont, Calif. –  November 9, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using  a novel transdermal delivery technology, announced publication in the current issue of the Journal of Clinical Endocrinology and Metabolism of results from a positive phase 2 study of its rapid-...
Jul 7, 2009
Fremont, Calif. – July 7, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that the company has closed a new round of financing in the amount of $30 million.Nomura Phase4 Ventures led the round and all of the ...
Jun 11, 2009
Fremont, Calif. – June 11, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Thorsten von Stein, MD, PhD has joined the company as Chief Medical Officer.  Dr. von Stein reports to Zosano Chair and CEO, Gail Sc...
Jun 11, 2009
Fremont, Calif. – June 11, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Thorsten von Stein, MD, PhD has joined the company as Chief Medical Officer.  Dr. von Stein reports to Zosano Chair and CEO, Gail Sc...
Apr 4, 2009
Fremont, Calif. – April 4, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using  a novel transdermal delivery technology, today presented positive results from its phase 2 study of the ZP-PTH rapid delivery patch for the treatment of osteoporosis at the 8th International Symposi...
Mar 3, 2009
Fremont, Calif. – March 31, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that an abstract detailing results of its Phase 2 study of ZP-PTH, a proprietary transdermal patch formulation of parathyroid hormone (PTH) for th...
Jan 19, 2009
Fremont, Calif., January 19, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that Dr. Peter Daddona, the company’s chief scientific officer, will present at the 13th Annual Drug Delivery Partnerships Meeting in Las Ve...
Page: FirstPrevious ...
9
NextLast
= add release to Briefcase